Clinical Trial

Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

Study acronym: INSPIRE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to address several key questions regarding the use of inclisiran in real-world clinical practice in Spain.
Protocol Amendment History 2 changes
notable Enrollment increased: 198 -> 219 participants 2026-08-08
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-02
Trial Details
NCT Number NCT06958315
Lead Sponsor Novartis Pharmaceuticals
Conditions Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia
Enrollment 219 participants
Start Date 2025-06-16
Primary Completion 2027-05-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-07